Projects per year
Personal profile
Biography
Professor Andrew Wei is a Victorian Cancer Agency Research Fellow and Haematologist at the Alfred Hospital. Andrew conducts clinical and translational AML research through dual appointments at the Alfred Hospital and Monash University.
After completing doctoral studies at the Walter and Eliza Hall Institute of Medical Research in 2005, he joined the Alfred Hospital in 2008 to develop the AML research program. He has been the AML disease group chairperson for Australasian Leukaemia and Lymphoma Group since 2009 and has led multiple nationwide cooperative group studies as chief investigator. His doctoral research studies contributed to discoveries elucidating the functional interaction between Bcl-2 family members (Molecular Cell 2005;17(3):393-403), the role of Mcl-1 in cancer susceptibility to ABT-737 (Cancer Cell. 2006;10(5):389-99) and the pro-survival function of the EBV Bcl-2 homologue BHRF-1 (PLoS Pathogens 2010;6[12]).
Professor Wei is an executive member of the ALLG Scientific Advisory Committee, a member of the National Medical and Scientific Advisory Committee of the Leukaemia Foundation of Australia and Head of Leukaemia Research at the Alfred hospital. He sits on the International Steering Committee for Celgene providing expert advice on AML. To enhance translational research, Dr Wei has established the Alfred Haematology Tissue Bank, the diagnostic molecular haematology laboratory and a pre-clinical research laboratory to focus on the role of targeting survival pathways in AML.
Related Links:
- Australian Centre For Blood Diseases, Leukaemia Research Group Leader http://www.acbd.monash.org/research/leukaemia-tr-group.html
- Professional Profile www.acbd.monash.org/staff/wei.html
Research interests
Dr. Wei's research focuses on the mechanisms by which cancer cells co-opt and coerce intracellular signalling pathways to promote deregulated cell survival, proliferation and growth. Through the molecular analysis of intracellular signalling pathways, Dr. Wei's laboratory seeks to identify new therapeutic targets in leukaemia.
Projects:
- Targetting 'survival kinases' in leukemic stem and progenitor cells
- The role of inositol phosphatases in regulating normal and malignant hemopoiesis
- Human models of AML
Monash teaching commitment
2007 - Present : Adjunct senior lecturer
Clinical activities
Investigator initiated AML trail funding:
- Phase 1 study of RAD001 and low dose ara-C for elderly AML
- Phase 1 study of azacitidine and lenalidomide as maintenance therapy in AML
- Phase 1 study of azacitidine and everolimus in relapsed AML
- Phase 1 multicentre ALLG study of lenalidomide maintenance therapy in AML
- Phase 2 randomised controlled multicentre ALLG study of Sorafenib in FLT3-ITD AML
- Phase 2 randomised multicentre ALLG study of high-dose lenalidomide and azacitidine and depsipeptide in relapsed AML
Cooperative Group Studies Local Site PI:
- Phase 3 study: ALLG AML M12 study
- Phase 2 study: ALLG APML M4 study
- Phase 2/3: UK MRC16 AML study
Company sponsored studies as local site PI:
- Phase 2 study: CEP-701 in relapsed AML
- Phase 2 study: AS1411 in relapsed AML
- Phase 2 study: Midostaurin in systemic mastocytosis
- Phase 2/3 study: AZD1152 in older AML
- Phase 3 study: PKC412 in AML
- Phase 3 study: Amonafide in secondary AML
- Phase 3 study: Elacytarabine in relapsed AML
- Phase 3: Voreloxin in relapsed AML
- Phase 1: KB004 in advanced haematological malignancies
- Phase 1: Meisoindigo in AML unfit for chemotherapy
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Acute myeloid leukaemia
- Azacytidine
- BH3
- Bcl-2
- Lenalidomide
- Leukaemia Foundation
- Leukemia
- Lymphoma
- Mcl-1
- Relapse and refractory
- Research Fellow
- Victorian Cancer Agency
- clinical AML
- leukaemic stem cells
- translational AML
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician's Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia
Wei, A., Hodges, G., Purtill, D., Bennett, S., Hiwase, D. K., Tate, C., Enjeti, A., Bhattacharyya, A. & Tan, P.
31/08/21 → 31/12/24
Project: Research
-
INTERCEPT (Investigating Novel Therapy to target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): a multi-arm, precision-based, recursive, platform trial
Wei, A., DiNardo, C., Roberts, A. W., Daver, N., Reynolds, J., Blombery, P. A., Marlton, P. & Curtis, D.
1/07/21 → 30/06/25
Project: Research
-
A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations.
Wei, A., Kennedy, N., Bajel, A. & Flemming, S.
2/12/20 → 31/12/25
Project: Research
-
An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukaemia.
Flemming, S., Wei, A., Bajel, A. & Kennedy, N.
20/10/20 → 31/12/25
Project: Research
-
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
Blombery, P., Lew, T. E., Dengler, M. A., Thompson, E. R., Lin, V. S., Chen, X., Nguyen, T., Panigrahi, A., Handunnetti, S. M., Carney, D. A., Westerman, D. A., Tam, C. S., Adams, J. M., Wei, A. H., Huang, D. C. S., Seymour, J. F., Roberts, A. W. & Anderson, M. A., 24 Feb 2022, In: Blood. 139, 8, p. 1198-1207 10 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access9 Citations (Scopus) -
Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system
Parker, C., Ayton, D., Zomer, E., Liew, D., Vassili, C., Fong, C. Y. & Wei, A., Feb 2022, In: Leukemia Research. 113, 7 p., 106786.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system
Parker, C., Ayton, D., Zomer, E., Liew, D., Vassili, C., Fong, C. Y. & Wei, A., Jan 2022, In: Leukemia Research. 112, 7 p., 106748.Research output: Contribution to journal › Article › Other › peer-review
Open Access -
Erratum: “Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system” (Leukemia Research (2022) 112C, (106748), (S0145212621017495), (10.1016/j.leukres.2021.106748))
Parker, C., Ayton, D., Zomer, E., Liew, D., Vassili, C., Fong, C. Y. & Wei, A., Apr 2022, In: Leukemia Research. 115, 1 p., 106784.Research output: Contribution to journal › Comment / Debate › Other › peer-review
Open Access -
FLT3-ITD signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescue
Loo, S. & Wei, A. H., Apr 2022, In: Haematologica. 107, 4, p. 783-784 2 p.Research output: Contribution to journal › Editorial › Other › peer-review
Open Access
Prizes
-
2003: Albert Baikie Award, Best Oral Abstract Presentation, Haematology Society of Australia
Wei, Andrew (Recipient), 2004
Prize: Prize (including medals and awards)
-
2003: Young Investigator Award, Best Oral Abstract Presentation, Annual Scientific Meeting, Hobart
Wei, Andrew (Recipient), 2003
Prize: Prize (including medals and awards)
-
2004: New Investigator Award, Best Oral Abstract, Annual Scientific Meeting, Canberra
Wei, Andrew (Recipient), 2004
Prize: Prize (including medals and awards)
Activities
- 8 Membership of an advisory panel/policy group/ board
-
Australasian Leukaemia & Lymphoma Group (External organisation)
Andrew Wei (Member)
1 Jan 2012Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board
-
AUSTRALIAN SOCIETY OF THROMBOSIS AND HAEMOSTASIS (External organisation)
Andrew Wei (Member)
1 Jan 2012Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board
-
EUROPEAN HAEMATOLOGY ASSOCIATION (External organisation)
Andrew Wei (Member)
1 Jan 2012Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board
-
The Royal Australasian College of Physicians (External organisation)
Andrew Wei (Member)
1 Jan 2012Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board
-
AMERICAN SOCIETY OF HAEMATOLOGY (External organisation)
Andrew Wei (Member)
1 Jan 2012Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board